|
|
Article: Bristol-Myers Squibb Receives FDA Approval for TEQUIN(TM), A New Type of Quinolone Antibiotic.
- Article from:
- PR Newswire
- Article date:
- January 18, 2000
CopyrightCOPYRIGHT 2000 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New, Advanced Quinolone Antibiotic is Designed to Treat Indications Including
Respiratory Tract Infections
PRINCETON, N.J., Jan. 18 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) has announced that TEQUIN(TM) (gatifloxacin), a new type of quinolone antibiotic, has been approved by the U.S. Food and Drug Administration for indications including the treatment of community-acquired respiratory tract infections (RTIs). TEQUIN was designed with a unique 8-methoxy structure that appears to enhance bactericidal action and decrease the rate of the development of resistance of gram-positive bacteria. TEQUIN is the first and only antibiotic of this ...